Epidemic

NFID Announces 2024 Recipients of Prestigious Awards

Retrieved on: 
Tuesday, April 9, 2024
RN, Maxwell Finland Award, COVAX, Health equity, HIV, Biomedical Research, Health, Patient, Epidemic, Infection, Rockefeller Foundation, Vaccine, Ageing, AIDS, International, Education, Policy, Master of Science, Woman, Gavi, World Health Organization, Immunization, Safety, Disease, Global health, Public, Research, Death, Mentorship, NFID, MPH, National Academy of Medicine, CPNP, COVID-19, IAVI, National academy, Developed country

BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work. The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:

Key Points: 
  • BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work.
  • The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:
    Seth F. Berkley, MD, of the Pandemic Center of Brown University, will receive the 2024 Jimmy and Rosalynn Carter Humanitarian Award in recognition of his work as an innovative entrepreneur, a pioneer in global health, and a champion of equitable access to vaccines.
  • The awards will be presented at the 2024 NFID Awards Gala and Silent Auction, a black-tie fundraising event scheduled for September 19, 2024, in Washington, DC.
  • All contributions support the NFID mission to educate the public and healthcare professionals on the prevention and treatment of infectious diseases.

Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.

Retrieved on: 
Thursday, March 21, 2024
Control, EST, Congress, Lyme disease, CEPI, Coalition, Saint-Herblain, Pan American Health Organization, Walter, PAHO, International Vaccine Institute, Chikungunya, Epidemic, Drug, IVI, CDC, Process, VLA, Euronext Paris, Market access, ACIP, The 24th

The Company will have a display in the exhibit area of the congress at booth #433.

Key Points: 
  • The Company will have a display in the exhibit area of the congress at booth #433.
  • There will be two sessions, from 11:40 to 12:20 EST and again from 12:30 to 1:10pm EST.
  • Advisory Committee on Immunization Practices (ACIP)1 and these recommendations were adopted by the Centers for Disease Control and Prevention (CDC)2.
  • Additionally, Valneva CEO Thomas Lingelbach will present the Best Production / Process Development award at the event.

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

Retrieved on: 
Wednesday, March 20, 2024
MERS, Patient, Ethics, Epidemic, NUC, Group 3, Clinical trial, Liver, Depreciation, Vaccine, Hepatitis, PD-1, Research, Coalition, Arbutus, Hepatology, Coeliac disease, Nivolumab, Safety, Immune system, CHB, Prostate cancer, CEPI, AASLD, University, Șaeș, Cancer, HBV, Conference, AstraZeneca, Autoimmunity, Infection, Human papillomavirus infection, Oxford University Innovation, SNAP, HPV, APOLLO, Pharmaceutical industry

Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.

Key Points: 
  • Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
  • We presented the final data in June 2023 at the European Association for the Study of the Liver Congress 2023 – The International Liver CongressTM.
  • We presented this data during an oral presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023.
  • In November 2023, we announced the company’s renaming as Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines.

New Fortress Energy Completes Previously Announced Acquisition and Transfer of 1.6 GW, 15-year Contracted Power Asset in Brazil

Retrieved on: 
Wednesday, March 20, 2024
Energy, Utilities, Oil, Gas, Failure, Health, Natural gas, Communication, Partnership, Norsk Hydro, Epidemic, Acquisition, Security (finance), Risk, Wes Edens, NFE, Ship, Safety, Pandemic, PPA, COD, Renewable energy

Construction activities for the 1.6 GW power plant have commenced at NFE’s site adjacent to our existing LNG terminal located in Barcarena, Brazil.

Key Points: 
  • Construction activities for the 1.6 GW power plant have commenced at NFE’s site adjacent to our existing LNG terminal located in Barcarena, Brazil.
  • This transaction represents the value of our operational LNG terminals in Brazil and we appreciate the partnership with Denham Capital to move quickly to transfer this PPA and begin construction,” said Andrew Dete, Managing Director of New Fortress Energy.
  • For additional information on the acquisition, please reference the press release issued on December 27, 2023 on our investor relations website at https://ir.newfortressenergy.com/investor-relations.
  • About New Fortress Energy Inc.
    New Fortress Energy Inc. (NASDAQ: NFE) is a global energy infrastructure company founded to help address energy poverty and accelerate the world’s transition to reliable, affordable, and clean energy.

New Fortress Energy Announces Transformative Transactions in Puerto Rico

Retrieved on: 
Monday, March 18, 2024
Alternative Energy, Energy, Other Energy, Oil, Gas, Failure, Health, Corps, Natural gas, Communication, Peptide, COVID-19, Coronavirus, Epidemic, Engineer, Security (finance), Risk, Plant, Wes Edens, NFE, Ship, Safety, Pandemic, PREPA, Cryptocurrency

New Fortress Energy Inc. (NASDAQ: NFE) (the “Company”) is pleased to announce two transactions that further solidify our commitment to providing affordable and sustainable energy solutions in Puerto Rico.

Key Points: 
  • New Fortress Energy Inc. (NASDAQ: NFE) (the “Company”) is pleased to announce two transactions that further solidify our commitment to providing affordable and sustainable energy solutions in Puerto Rico.
  • The expanded volumes under the contract will enable conversion of other plants on the island from diesel to gas, providing lower cost, cleaner energy to Puerto Rico.
  • “We entered the Puerto Rico market in 2017 based on the island’s emergency need for natural gas and power.
  • About New Fortress Energy Inc.
    New Fortress Energy Inc. (NASDAQ: NFE) is a global energy infrastructure company founded to help address energy poverty and accelerate the world’s transition to reliable, affordable, and clean energy.

Joint Statement from the Co-Chairs of the Special Advisory Committee on the Epidemic of Opioid Overdoses - Latest National Data on Substance-Related Harms

Retrieved on: 
Wednesday, March 27, 2024
Consciousness, Risk, Opioid, COVID-19, Patient, Benzodiazepine, Ageing, Inhalation, Public, Naloxone, Portrait, Epidemic, Male, Special Advisory Committee, Xylazine, Government, Fentanyl, Pharmaceutical industry

These numbers are the largest observed since data collection  began in 2016, signifying the ongoing worsening of this urgent public health crisis.

Key Points: 
  • These numbers are the largest observed since data collection  began in 2016, signifying the ongoing worsening of this urgent public health crisis.
  • These latest data show that in Canada between January and September 2023, there were 5,975 apparent opioid-related deaths and 4,646 hospitalizations for opioid-related poisonings.
  • New data from emergency departments (ED) show that during the same period, there were 21,708 reported opioid poisoning ED visits, which is 80 per day.
  • While it may take time to see results, everything we do to help combat this crisis and save lives is critical.

Healthcare Analytics Market Size to Grow by USD 66.54 billion from 2024 to 2028, Market growth at 24.79% CAGR expected during the forecast period, Technavio

Retrieved on: 
Thursday, March 14, 2024
Komodo, Cloud, Conditional sentence, Informatics, Corp, Component, Health, UnitedHealth Group, Epidemic, IQVIA, Health care, Artificial intelligence, Telehealth, Health information management, USD, Oracle Corporation, Risk, Policy, Cerner, Electronic health record, Information management, SAS Institute, Financial management, Automation, Documentation, Health information exchange, Risk management, Intelligence, Data mining, AI, Veeva Systems, Machine learning, Service, IBM, Mining, Growth, Big data, McKesson Corporation, Health informatics, EHR, Hardware, Retail

The report provides actionable insights and estimates the contribution of all regions to the growth of the global healthcare analytics market.

Key Points: 
  • The report provides actionable insights and estimates the contribution of all regions to the growth of the global healthcare analytics market.
  • The Healthcare Analytics Market is experiencing significant growth driven by advancements in healthcare data analytics, which encompass clinical, predictive, prescriptive, and descriptive analytics.
  • The Healthcare Analytics Market is witnessing substantial growth driven by advancements in healthcare data analytics, encompassing clinical, predictive, prescriptive, and descriptive analytics.
  • Emerging technologies drive market opportunities amidst challenges, positioning the healthcare analytics market for substantial growth and dynamic evolution.

Navitas Semiconductor Announces Record Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 29, 2024
Internet, EV, Failure, Silicon, Zeekr, Research, Epidemic, Part, Growth, OPPO, Samsung, Original equipment manufacturer, BYD, Conference, Smart, GAAP, COVID-19, Silicon carbide, Part 1, Geely, Gallium nitride, Probability, Risk, Volvo, Hyundai, Video game

Gross Margin: GAAP gross margin for the fourth quarter of 2023 was 42.2%, compared to 40.6% in the fourth quarter of 2022 and 32.3% for the third quarter of 2023.

Key Points: 
  • Gross Margin: GAAP gross margin for the fourth quarter of 2023 was 42.2%, compared to 40.6% in the fourth quarter of 2022 and 32.3% for the third quarter of 2023.
  • Non-GAAP gross margin for the fourth quarter of 2023 was 42.2% compared to 40.6% for the fourth quarter of 2022 and 42.1% for the third quarter of 2023.
  • Loss from Operations: GAAP loss from operations for the quarter was $26.8 million, compared to a loss of $31.2 million for the fourth quarter of 2022 and a loss of $28.6 million for the third quarter of 2023.
  • On a non-GAAP basis, loss from operations for the quarter was $9.7 million compared to a loss of $12.4 million for the fourth quarter of 2022 and a loss of $8.7 million for the third quarter of 2023.

AngloGold Ashanti Chairman Maria Ramos to Retire; Director Jochen Tilk Appointed Chairman

Retrieved on: 
Friday, March 8, 2024
Professional Services, Natural Resources, Mining, Minerals, Finance, AngloGold Ashanti, Ethics, Epidemic, Compensation, F-4, PotashCorp, Government, Form, Annual report, Pandemic, Health, COVID-19, Nutrient, Gold, AGM, Public expenditure, Risk, Accident, Management

AngloGold Ashanti plc announces that Ms. Maria Ramos, independent non-executive director and chairman of the Board of Directors, has elected not to stand for re-election at the upcoming annual general meeting of shareholders on 28 May 2024.

Key Points: 
  • AngloGold Ashanti plc announces that Ms. Maria Ramos, independent non-executive director and chairman of the Board of Directors, has elected not to stand for re-election at the upcoming annual general meeting of shareholders on 28 May 2024.
  • Ms. Ramos served as director of AngloGold Ashanti since 1 June 2019 and Chairman since 5 December 2020.
  • Mr. Tilk has been an independent non-Executive Director of AngloGold Ashanti since 1 January 2019 and is Chairman of the board’s Investment Committee.
  • “We are grateful for Maria’s enormous contribution to AngloGold Ashanti during her tenure as Chairman,” said AngloGold Ashanti CEO Alberto Calderon.

CI&T Provides Preliminary Results for the Fourth Quarter of 2023 and the Full Year of 2023 and Business Outlook for 2024

Retrieved on: 
Thursday, March 7, 2024
Apps, Applications, Technology, Mobile, Wireless, Other Technology, Software, Networks, IOT (Internet of Things), Data Management, Artificial Intelligence, Acquisition, Hamas, AI, CINT, Risk, Annual report, Epidemic, Growth, Nature, Government, Pandemic, Income tax, Translation, Bank statement, Net income, FX, Depreciation, Bookkeeping

From 2019 to 2023, our revenue CAGR was 35%, of which 60% originated from mature economies nowadays, especially the US.

Key Points: 
  • From 2019 to 2023, our revenue CAGR was 35%, of which 60% originated from mature economies nowadays, especially the US.
  • CI&T ended 4Q23 with 6,111 employees, fairly stable compared to the third quarter of 2023.
  • Cash generated from operating activities rose 158.3% in 2023 to R$ 414.3 million in 2023 from R$ 160.4 million in 2022.
  • While we expect that our results will be consistent with these preliminary and unaudited estimates, our actual results may differ materially from these preliminary estimates.